Authors: Mohan, DS et al
Source: International Journal of Radiation Oncology, Biology and Physics Vol. 42 No. 5 p.981, December 1, 1998
The authors retrospectively reviewed the charts of one hundred and two patients, all of whom were age greater than seventy and treated for glioblastoma between 1977 and 1996. Fifty-eight patients were treated with definitive radiation, defined as receiving a dose greater than 5500cGy. Nineteen patients received palliative radiation (lower doses). Patients were categorized by whether they received optimal treatment (gross total or subtotal resection and definitive post-operative radiation) or suboptimal treatment (surgery alone or surgery followed by palliative radiation). Thirty-nine patients who underwent optimal treatment and had a Karnofsky performance status of 70 or greater were considered to have a favorable prognosis.
The median overall survival for the group as a whole was 5.3 months. Comparing patients who received definitive versus palliative radiation, the median survival was 7.3 verses 4.5 months favoring definitive radiation. Patients undergoing biopsy alone had the worst median survival of any sub-group, 1.2 months.
Optimally treated patients had a significantly longer median survival (7.4 moths) compared to 2.4 months for suboptimally treated patients. Similarly, the group of patients with a favorable prognosis survived significantly longer than those with poor prognosis.
In order to compare results of this report with randomized trials of younger patients; the authors analyzed survival according to the Radiation Therapy Oncology Group (RTOG) prognostic categories. RTOG group IV is defined by patient age greater than fifty, Karnofsky performance status greater than 70, able to work, and undergoing a resection. RTOG group VI is defined as patient age greater than 50 and performance status less than 70 or a higher performance status but treatment with biopsy and radiation dose less than 5400cGy. RTOG group V includes patient age greater than 50 who do not meet the criteria for group IV or VI.
The median survival for these three RTOG prognostic groups was significantly different: 9.2 months, 6.6 months and 3.1 months for groups IV, V and VI respectively. These results compare poorly to a study published by the RTOG in which median survival was 11.1 months, 8.9 months and 4.6 months for groups IV, V and VI respectively. However, the RTOG patients were all less than seventy years old.
Aggressive treatment of selected elderly patients with glioblastoma appears warranted given the improved survival following aggressive treatment. Patients age greater than seventy who should be considered for aggressive treatment include those with good performance status and no co-existing medical conditions. Treatment for elderly patients who are in poor medical condition must be individualized.
OncoLink is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through OncoLink should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem or have questions or concerns about the medication that you have been prescribed, you should consult your health care provider.
Information Provided By: www.oncolink.org | © 2016 Trustees of The University of Pennsylvania